Healthcare Industry News: Kerberos Proximal Solutions
News Release - June 1, 2006
Kerberos Completes First Clinical Cases with New Peripheral Rinspiration(R) SystemCUPERTINO, Calif.--(HSMN NewsFeed)--June 1, 2006--Kerberos Proximal Solutions Inc. has successfully completed its first series of cases with the new Peripheral Rinspiration® Catheter System. The Peripheral Rinspiration System is designed to remove thrombi (blood clots) and emboli (debris) from the peripheral vasculature.
In the cases just completed, the Peripheral Rinspiration Catheter was used during endovascular procedures to restore or improve blood flow in patients experiencing acute or chronic lower limb occlusions. Physicians found Rinspiration to be especially effective when used pre- and post-intervention with balloon angioplasty, stent placement, and/or atherectomy.
Dr. Bernard Reen III, FACC of Presbyterian Hospital in Charlotte, N.C., was among those to use the Peripheral Rinspiration System to re-establish flow in a patient case with an occluded Superficial Femoral Artery (SFA). According to Dr. Reen, "The Rinspiration System exceeded my expectations. I was able to remove a significant amount of clot prior to performing an atherectomy. Post procedure I again used Rinspiration to retrieve still more debris. Rinspiration proved to be an excellent choice in clearing the vessel of potential debris both pre- and post-treatment."
Rinspiration® is an innovative technology that allows physicians to enter a vessel to use therapeutic solutions to simultaneously rinse and aspirate embolic debris and thrombus out to the vessel wall. This combined action is unique to Rinspiration, and effectively helps prevent debris from potentially moving downstream and putting patients at risk of peripheral occlusions within the microvasculature.
Dr. Barry Weinstock, Florida Hospital-Orlando in Orlando, Fla., has performed several cases using the Peripheral Rinspiration System in occluded lower limb vessels. "The device is extremely easy to use. It has repeatedly surprised me by removing an extensive amount of debris from vessels that appear angiographically 'normal,' even post-stenting," said Dr. Weinstock. "Preliminary use of the product suggests that Rinspiration may be valuable in elective procedures for rinsing and aspirating chronic thrombus, or 'cleaning up' after an interventional treatment device has been applied, such as PTA, stent placement, or atherectomy."
Up to 30 million people in the United States are afflicted with peripheral vascular disease (PVD). The most common form of PVD involves plaque buildup on the interior artery wall that eventually leads to reduced blood flow and development of a blood clot. "The unique ability to simultaneously rinse and aspirate fluid-prescribed therapies in an easy-to-use, hand-held device reaffirms the treatment opportunity that this innovative technology holds for the market," said King Nelson, president and CEO, Kerberos Proximal Solutions.
Kerberos will showcase the Peripheral Rinspiration System at major interventional meetings throughout 2006, including the Vascular Annual Meeting, June 1-4; the June 14-17 Live Symposium of Complex Coronary and Vascular Cases; and others.
Kerberos Proximal Solutions Inc. is a privately held medical device company headquartered in Cupertino, Calif. Founded in 2001, Kerberos is dedicated to developing innovative solutions to treat vascular disease. Investors in Kerberos include Three Arch Partners, Boston Scientific Corp. (NYSE: BSX ), and Research Corp. Technologies.
Source: Kerberos Proximal Solutions
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.